Elevated bilirubin after gastric sleeve surgery is a concern that patients and clinicians should take seriously, as it can signal a range of conditions from benign to potentially serious. Sleeve gastrectomy does not reroute the bile ducts, yet the rapid weight loss that follows significantly increases the risk of gallstone formation and places considerable metabolic stress on the liver. Transient rises in liver function tests are not uncommon in the early postoperative period, but persistent or symptomatic hyperbilirubinaemia always warrants prompt clinical assessment. This article explores the causes, symptoms, diagnostic approach, and NHS management pathways relevant to raised bilirubin following gastric sleeve surgery.

Why Bilirubin Levels May Rise After Gastric Sleeve Surgery

Bilirubin rises after gastric sleeve surgery primarily due to rapid weight loss increasing gallstone risk and metabolic stress on the liver, rather than direct alteration of bile ducts. Persistent or symptomatic hyperbilirubinaemia always requires clinical assessment.

Bilirubin is a yellow pigment produced during the normal breakdown of red blood cells. It is processed by the liver, stored in the gallbladder, and excreted via bile into the digestive tract. When this process is disrupted, bilirubin can accumulate in the bloodstream, leading to elevated serum levels — a condition that may present as jaundice, fatigue, or dark urine.

Not sure if this is normal? Chat with one of our pharmacists →

It is helpful to distinguish between two types of elevated bilirubin. Unconjugated (indirect) hyperbilirubinaemia suggests overproduction or impaired conjugation of bilirubin — for example, due to haemolysis, ineffective erythropoiesis, or a condition such as Gilbert's syndrome. Conjugated (direct) hyperbilirubinaemia points towards cholestasis or biliary obstruction, and warrants more urgent investigation.

Gastric sleeve surgery (sleeve gastrectomy) involves the removal of approximately 75–80% of the stomach. Unlike Roux-en-Y gastric bypass, it does not reroute the bile ducts or small intestine, so it does not directly alter bile flow. However, the rapid weight loss that follows surgery significantly increases the risk of gallstone formation, which can in turn affect bilirubin metabolism. The liver is also under considerable metabolic stress as the body adapts to rapid weight loss, altered caloric intake, and significant hormonal shifts.

Transient derangements in liver function tests (LFTs) can occur in the early postoperative period, but persistent or symptomatic hyperbilirubinaemia always requires clinical assessment. Patients and clinicians should not assume that raised bilirubin is simply a normal part of recovery.

Common Causes of Elevated Bilirubin Following Bariatric Procedures

The most common causes include gallstone formation, pre-existing NAFLD/MASLD, Gilbert's syndrome unmasked by caloric restriction, nutritional deficiencies affecting red blood cell production, and drug-induced liver injury from postoperative medications.

Several well-recognised causes can contribute to elevated bilirubin after gastric sleeve surgery:

Non-alcoholic fatty liver disease (NAFLD, now also termed metabolic-associated steatotic liver disease or MASLD): Many patients undergoing bariatric surgery have pre-existing NAFLD, which is closely linked to obesity and insulin resistance. In the early postoperative period, rapid weight loss can transiently worsen hepatic inflammation before improvement occurs, leading to temporary rises in liver enzymes. Over 12–24 months, sustained weight loss generally leads to significant improvement in hepatic steatosis. NICE NG49 provides guidance on the assessment and management of NAFLD in the UK.

Gallstone formation: Rapid weight loss is a well-established risk factor for cholelithiasis. As fat is mobilised quickly, bile becomes supersaturated with cholesterol, promoting gallstone formation. Gallstones can obstruct the bile duct (choledocholithiasis), causing conjugated hyperbilirubinaemia. Some bariatric centres prescribe ursodeoxycholic acid (UDCA) prophylactically for up to 6 months post-surgery to reduce this risk; however, this use is off-label in the UK and is not universally recommended — practice varies between centres and should follow local protocols and consultant advice.

Gilbert's syndrome: This benign, inherited condition causes mildly elevated unconjugated bilirubin due to reduced UDP-glucuronosyltransferase activity. It may become more apparent during periods of physiological stress, fasting, or caloric restriction — all common after bariatric surgery. Gastric sleeve surgery does not cause Gilbert's syndrome, but the postoperative period may unmask it.

Nutritional deficiencies: Deficiencies in vitamin B12 and folate following surgery can lead to ineffective erythropoiesis, which may cause mild unconjugated hyperbilirubinaemia. Iron deficiency does not directly cause raised bilirubin and should not be considered a primary cause of hyperbilirubinaemia in this context.

Drug-induced liver injury (DILI): Postoperative medications, including analgesics and antibiotics, may occasionally cause hepatotoxicity, contributing to raised bilirubin. Patients and healthcare professionals should report any suspected adverse drug reactions via the MHRA Yellow Card scheme (yellowcard.mhra.gov.uk).

Symptoms and When to Seek Medical Advice

Jaundice, dark urine, pale stools, and right upper quadrant pain are key symptoms of elevated bilirubin. Jaundice with fever and rigors requires emergency care, while new painless jaundice warrants an urgent two-week-wait cancer referral.

Elevated bilirubin may present with a range of symptoms, some subtle and others more clinically significant. Patients should be aware of the following signs:

• Jaundice: Yellowing of the skin and whites of the eyes (scleral icterus) is the hallmark sign of hyperbilirubinaemia

• Dark urine: Tea- or cola-coloured urine suggests conjugated (direct) bilirubin is being excreted via the kidneys

• Pale or clay-coloured stools: This may indicate biliary obstruction, preventing bile from reaching the intestine

• Itching (pruritus): Bile salt deposition in the skin can cause generalised itching

• Fatigue and nausea: Non-specific but commonly reported alongside liver dysfunction

• Right upper quadrant pain: May suggest gallstone disease or hepatic inflammation

When to seek urgent or emergency care:

Patients should call 999 or attend A&E immediately if jaundice is accompanied by:

• High fever and rigors (suggesting cholangitis — a potentially life-threatening biliary infection requiring emergency hospital admission)

• Severe abdominal pain

• Confusion or altered consciousness

• Rapidly worsening jaundice

Patients should contact their GP promptly if they develop jaundice without the above features, or notice any of the symptoms listed above after gastric sleeve surgery.

New painless jaundice — particularly in the absence of pain or fever — is a recognised red flag for obstructive malignancy (such as pancreatic or bile duct cancer) and should prompt an urgent suspected cancer (two-week-wait) referral in line with NICE NG12. Patients should not self-manage jaundice or assume it is a normal part of recovery without professional assessment.

Diagnosis and Tests Used to Investigate High Bilirubin Levels

Investigation begins with fractionated liver function tests to distinguish conjugated from unconjugated hyperbilirubinaemia, followed by abdominal ultrasound as first-line imaging for suspected biliary pathology per NICE CKS guidance.

When elevated bilirubin is identified — either incidentally on routine blood tests or in response to symptoms — a structured diagnostic approach is essential. The first step is to determine whether the hyperbilirubinaemia is conjugated (direct) or unconjugated (indirect), as this distinction guides further investigation.

Initial blood tests typically include:

• Full liver function tests (LFTs): ALT, AST, ALP, GGT, albumin, and total/direct bilirubin

• Full blood count (FBC): To assess for anaemia

• Haemolysis screen: Reticulocyte count, blood film, LDH, and haptoglobin (direct antiglobulin test [DAT] if immune haemolysis is suspected)

• Coagulation screen (PT/INR): To evaluate synthetic liver function

• Renal function and electrolytes

• Nutritional markers: Vitamin B12, folate, ferritin, iron studies, vitamin D

• Viral hepatitis serology (hepatitis A, B, C, and E) when a hepatitic or cholestatic pattern is present or unexplained

• Autoimmune liver screen (ANA, SMA, AMA, IgG) if viral causes are excluded and liver enzyme abnormalities persist

Imaging investigations:

• Abdominal ultrasound is the first-line imaging modality for suspected biliary pathology, in line with NICE CKS guidance on gallstones. It can identify gallstones, biliary duct dilatation, and hepatic changes consistent with fatty liver disease.

• Magnetic resonance cholangiopancreatography (MRCP) is recommended if common bile duct obstruction is suspected but not confirmed on ultrasound. Endoscopic ultrasound (EUS) may be considered where available.

• CT abdomen is not first-line for biliary disease but may be used to exclude alternative structural pathology or complications.

Specialist investigations such as liver biopsy or endoscopic retrograde cholangiopancreatography (ERCP) are reserved for cases where the diagnosis remains unclear or therapeutic intervention is required (e.g., stone extraction).

In the bariatric setting, patients should ideally have baseline LFTs recorded preoperatively, enabling meaningful comparison postoperatively. Many NHS bariatric units include routine LFT monitoring at 3, 6, and 12 months post-surgery as part of their follow-up protocol, in line with BOMSS guidance.

Treatment Options and NHS Management Pathways

Treatment targets the underlying cause — gallstone-related obstruction may require ERCP or laparoscopic cholecystectomy, NAFLD improves with sustained weight loss, and nutritional deficiencies are corrected with BOMSS-recommended supplementation.

Management of elevated bilirubin after gastric sleeve surgery depends entirely on the underlying cause. There is no single treatment for hyperbilirubinaemia itself; rather, the focus is on identifying and addressing the root pathology.

Gallstone-related disease: If gallstones are confirmed as the cause of biliary obstruction, management may include:

• Ursodeoxycholic acid (UDCA): When used prophylactically after bariatric surgery, UDCA is off-label in the UK and is not universally recommended — its use is centre-specific and should follow local protocols. As a dissolution therapy, UDCA has a limited role and is generally reserved for selected non-surgical candidates with small, radiolucent cholesterol stones; patients should be counselled that efficacy is modest and recurrence is common after stopping treatment. Refer to the BNF and the relevant Summary of Product Characteristics (SmPC) for licensed indications.

• Acute cholangitis is a medical emergency requiring prompt hospital admission, intravenous antibiotics, and usually urgent ERCP. Patients with fever, rigors, jaundice, and right upper quadrant pain should be assessed in hospital without delay.

• ERCP with sphincterotomy for common bile duct stones

• Laparoscopic cholecystectomy for symptomatic gallbladder disease — this is a common procedure in the post-bariatric population and is well-supported within NHS surgical pathways

NAFLD/MASLD: Continued weight loss following bariatric surgery generally leads to significant improvement in hepatic steatosis over 12–24 months. Management focuses on optimising nutrition, maintaining physical activity, and avoiding hepatotoxic substances including alcohol and unnecessary medications. Risk stratification and management should follow NICE NG49.

Nutritional deficiencies: Supplementation with appropriate vitamins and minerals — as recommended by the British Obesity and Metabolic Surgery Society (BOMSS) — is essential. Standard post-sleeve supplementation typically includes a multivitamin, vitamin D, calcium, and vitamin B12, with additional supplementation guided by blood results.

Gilbert's syndrome: No treatment is required. Patients should be reassured that this is a benign condition, though they should avoid prolonged fasting and dehydration.

Drug-induced liver injury (DILI): The suspected causative agent should be reviewed and discontinued where clinically safe to do so. Suspected adverse drug reactions should be reported via the MHRA Yellow Card scheme (yellowcard.mhra.gov.uk).

Within NHS pathways, patients with persistent or unexplained elevated bilirubin should be referred to a hepatologist or gastroenterologist. Bariatric multidisciplinary teams (MDTs) — comprising surgeons, dietitians, physicians, and specialist nurses — play a central role in coordinating ongoing care.

Long-Term Liver Health Monitoring After Gastric Sleeve Surgery

BOMSS guidance recommends annual liver function tests and nutritional blood panels for life after gastric sleeve surgery, with non-invasive fibrosis assessment using FIB-4 score or FibroScan if LFTs remain persistently abnormal.

Long-term liver health monitoring is a critical but sometimes overlooked component of post-bariatric care. Whilst gastric sleeve surgery is associated with significant metabolic benefits — including improvements in type 2 diabetes, hypertension, and dyslipidaemia — its effects on the liver are complex and evolve over time.

In the majority of patients, liver function normalises and hepatic steatosis improves substantially within 12–24 months of surgery, as sustained weight loss reduces the metabolic burden on the liver. However, a subset of patients may develop or experience worsening of liver fibrosis. Increased alcohol consumption after bariatric surgery is a recognised concern; whilst the evidence is stronger for Roux-en-Y gastric bypass (due to altered alcohol absorption), patients who have undergone sleeve gastrectomy should also be advised to minimise alcohol intake, as the liver remains vulnerable during the period of metabolic adaptation.

Recommended monitoring strategies, in line with BOMSS guidance, include:

• Routine LFTs at 3, 6, and 12 months postoperatively, then annually for life

• Annual nutritional blood panel including FBC, renal function, LFTs, ferritin, folate, vitamin B12, vitamin D, calcium, and PTH (with zinc, selenium, and copper as locally indicated)

• Liver ultrasound if LFTs remain persistently abnormal

• Non-invasive fibrosis assessment using the FIB-4 score or NAFLD Fibrosis Score as a first step, with consideration of enhanced liver fibrosis (ELF) testing or transient elastography (FibroScan) per local pathways, in line with NICE NG49

• Alcohol screening using a validated tool (e.g., AUDIT-C) at follow-up appointments, with referral to alcohol support services if indicated

Patients should be encouraged to attend all scheduled follow-up appointments and to report any new symptoms promptly. Lifestyle factors — including a balanced diet rich in protein and micronutrients, regular physical activity, and minimising alcohol intake — remain the cornerstone of long-term liver health after bariatric surgery.

Healthcare professionals should remain vigilant for signs of progressive liver disease in this population, ensuring timely referral to hepatology services when indicated. With appropriate monitoring and support, the majority of patients can expect meaningful and sustained improvements in liver health following gastric sleeve surgery.

Frequently Asked Questions